Evidence map›Paper›PMID 29364894›Full record

ArticlePloS one2018

Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus.

Suzan Dahdal, Vasilios Devetzis, George Chalikias, Dimitrios Tziakas, Carlo Chizzolini, Camillo Ribi, Marten Trendelenburg, Ute Eisenberger, Thomas Hauser, Andreas Pasch and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Suzan DahdalDepartment of Nephrology and Hypertension lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0001-5533-2326
Vasilios DevetzisDepartment of Nephrology and Hypertension lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
George ChalikiasDepartment of Cardiology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Dimitrios TziakasDepartment of Cardiology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Carlo ChizzoliniDivision of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland.
Camillo RibiDivision of Clinical Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland.
Marten TrendelenburgDivision of Internal Medicine and Clinical Immunology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Ute EisenbergerDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Duisburg, Germany.
Thomas HauserImmunologie-Zentrum, Zurich, Switzerland.
Andreas PaschDepartment of Biomedical Research, University of Bern, Bern, Switzerland.
Uyen Huynh-DoDepartment of Nephrology and Hypertension lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Spyridon ArampatzisDepartment of Nephrology and Hypertension lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Swiss Systemic Lupus Erythematosus Cohort Study Group
University of Bern · CHDemocritus University of Thrace · GRImmunologie-Zentrum Zürich · CHUniversity Hospital of Basel · CHUniversity Hospital of Geneva · CHUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic lupus erythematosus (SLE) is associated with severe cardiovascular complications. The T50 score is a novel functional blood test quantifying calcification propensity in serum. High calcification propensity (or low T50) is a strong and independent determinant of all-cause mortality in various patient populations.

methodsA total of 168 patients with ≥ 4 American College of Rheumatology (ACR) diagnostic criteria from the Swiss Systemic lupus erythematosus Cohort Study (SSCS) were included in this analysis. Serum calcification propensity was assessed using time-resolved nephelometry.

resultsThe cohort mainly consisted of female (85%), middle-aged (43±14 years) Caucasians (77%). The major determinants of T50 levels included hemoglobin, serum creatinine and serum protein levels explaining 43% of the variation at baseline. Integrating disease activity (SELENA-SLEDAI) into this multivariate model revealed a significant association between disease activity and T50 levels. In a subgroup analysis considering only patients with active disease (SELENA-SLEDAI score ≥4) we found a negative association between T50 and SELENA-SLEDAI score at baseline (Spearman's rho -0.233, P = 0.02).

conclusionsDisease activity and T50 are closely associated. Moreover, T50 levels identify a subgroup of SLE patients with ongoing systemic inflammation as mirrored by increased disease activity. T50 could be a promising biomarker reflecting SLE disease activity and might offer an earlier detection tool for high-risk patients.

Indexed as

AdultCalcinosisCohort StudiesFemaleHumansLupus Erythematosus, SystemicMaleMiddle Aged

Identifiers

PMID29364894
PMCPMC5783342
OpenAlexW2791607745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.